» Articles » PMID: 30224644

Mutational Processes Shape the Landscape of TP53 Mutations in Human Cancer

Abstract

Unlike most tumor suppressor genes, the most common genetic alterations in tumor protein p53 (TP53) are missense mutations. Mutant p53 protein is often abundantly expressed in cancers and specific allelic variants exhibit dominant-negative or gain-of-function activities in experimental models. To gain a systematic view of p53 function, we interrogated loss-of-function screens conducted in hundreds of human cancer cell lines and performed TP53 saturation mutagenesis screens in an isogenic pair of TP53 wild-type and null cell lines. We found that loss or dominant-negative inhibition of wild-type p53 function reliably enhanced cellular fitness. By integrating these data with the Catalog of Somatic Mutations in Cancer (COSMIC) mutational signatures database, we developed a statistical model that describes the TP53 mutational spectrum as a function of the baseline probability of acquiring each mutation and the fitness advantage conferred by attenuation of p53 activity. Collectively, these observations show that widely-acting and tissue-specific mutational processes combine with phenotypic selection to dictate the frequencies of recurrent TP53 mutations.

Citing Articles

Mis-splicing drives loss of function of p53E224D point mutation.

Lock I, Leisenring N, Floyd W, Xu E, Luo L, Ma Y PLoS One. 2025; 20(3):e0318856.

PMID: 40043089 PMC: 11882087. DOI: 10.1371/journal.pone.0318856.


The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers.

Bayraktar R, Tang Y, Dragomir M, Ivan C, Peng X, Fabris L Sci Adv. 2025; 11(8):eado2830.

PMID: 39970212 PMC: 11837999. DOI: 10.1126/sciadv.ado2830.


Association of Germline Variant and Choledochal Cyst among Clinically Diagnosed Filipino Pediatric Patients.

Opiso D, Gregorio G, Silao C Acta Med Philipp. 2025; 59(2):7-14.

PMID: 39967707 PMC: 11831089. DOI: 10.47895/amp.vi0.9091.


Assessing germline TP53 mutations in cancer patients: insights into Li-Fraumeni syndrome and genetic testing guidelines.

Danishevich A, Fedorova D, Bodunova N, Makarova M, Byakhova M, Semenova A Hered Cancer Clin Pract. 2025; 23(1):5.

PMID: 39962599 PMC: 11834258. DOI: 10.1186/s13053-025-00307-w.


Integrative machine learning model of RNA modifications predict prognosis and treatment response in patients with breast cancer.

Wang T, Wang S, Li Z, Xie J, Jia Q, Hou J Cancer Cell Int. 2025; 25(1):43.

PMID: 39948551 PMC: 11827143. DOI: 10.1186/s12935-025-03651-y.


References
1.
Kato S, Han S, Liu W, Otsuka K, Shibata H, Kanamaru R . Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003; 100(14):8424-9. PMC: 166245. DOI: 10.1073/pnas.1431692100. View

2.
Zhang Y, Xiong Y, Yarbrough W . ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998; 92(6):725-34. DOI: 10.1016/s0092-8674(00)81401-4. View

3.
Hsu I, Metcalf R, Sun T, Welsh J, Wang N, Harris C . Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991; 350(6317):427-8. DOI: 10.1038/350427a0. View

4.
Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D . Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A. 1999; 96(26):14973-7. PMC: 24757. DOI: 10.1073/pnas.96.26.14973. View

5.
Clarke A, Purdie C, Harrison D, Morris R, Bird C, Hooper M . Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993; 362(6423):849-52. DOI: 10.1038/362849a0. View